Research programme: exosome therapeutics - ArunA Biomedical

Drug Profile

Research programme: exosome therapeutics - ArunA Biomedical

Alternative Names: AB 126

Latest Information Update: 16 Apr 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator ArunA Biomedical
  • Developer ArunA Biomedical; Augusta University; University of Georgia
  • Class Neuroprotectants
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes - Neurodegenerative disorders; Stroke

Highest Development Phases

  • Preclinical Stroke
  • Research CNS disorders; Neurodegenerative disorders

Most Recent Events

  • 12 Apr 2018 Pharmacodynamics data from a preclinical trial in Stroke released by ArunA Biomedical
  • 10 Jan 2018 Research programme: exosome therapeutics - ArunA Biomedical is available for licensing as of 10 Jan 2018.
  • 03 Jan 2018 ArunA Biomedical plans first-in-human trials for AB 126 for Stroke in 2019 (ArunA Biomedical, January 2018)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top